Pathology & Genomics
Pathology & Genomics
批准号:
10673949
负责人:
David A Barbie
金额:
$30.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-01 至 2027-07-31
关键词:
AllelesAnatomyAntibodiesAreaBiochemical PathwayBiochemical ProcessBiologicalBiological AssayBiological MarkersCancer BiologyCancer CenterCaringCellsCertificationClinicalClinical PathologyClinical TreatmentComplementCustomDana-Farber Cancer InstituteDatabasesDetection of Minimal Residual DiseaseDevelopmentDiagnosisDiseaseEpidermal Growth Factor ReceptorErlotinibEtiologyExpression ProfilingGefitinibGene Expression ProfilingGeneticGenomicsGenotypeGoalsHistologicHybridsImageImmuneImmunofluorescence ImmunologicImmunohistochemistryImmunophenotypingIn SituIndividualInternationalInterventionIonsKnowledgeLaboratoriesMalignant NeoplasmsMalignant neoplasm of lungManualsMassive Parallel SequencingMeasuresMedicineMicroscopicMolecularMolecular GeneticsMonitorMultiplexed Ion Beam ImagingMutationOncogenicPathologistPathologyPatient MonitoringPatient SelectionPatientsPeriodicityPlasmaProceduresProteinsProtocols documentationQuality ControlRNA analysisROS1 geneReproduction sporesResearchResearch PersonnelResourcesSamplingScanningSelection for TreatmentsSeminalServicesSlideSpecimenStructure of parenchyma of lungSupervisionSystemTechniquesTechnologyTissue BanksTissue MicroarrayTissue SampleTissuesTranscriptTranslational ResearchTumor TissueValidationVertebral columnWorkautomated image analysisautomated segmentationcancer cellcrizotinibdesigndetection assayimmune cell infiltrateimmunoregulationimprovedinhibitorinnovationmolecular pathologynano-stringnext generation sequencingnovelnovel markerprotein biomarkersprotein expressionquality assuranceresponsesample collectionsequencing platformskillsstandard of caretranscriptomicstreatment and outcometumortumor DNAtumor microenvironment
中文摘要
项目摘要:
整合病理学和基因组学核心为肺癌样本提供最先进的分析服务
从最初的样品处理和加工到显微镜分析,
解剖病理学家,免疫表型分析,分子遗传学和基因组分析。这项工作
构成了肺癌管理的支柱,并使诊断和适当的治疗选择
对于所有类型的肺癌患者,还可以研究癌症生物学,病因学,
管理我们的病理学核心支持的工作,导致了重大进展的理解,
肺癌生物学及其相关管理,包括以下重要性的开创性发现:
肺癌中EGFR、ALK、ROS 1和MET的突变,其诊断和管理已成为
这一医学领域的国际护理标准。同样,我们打算继续我们的工作,
通过支持本文提出的新项目,
结合标准护理和创新的新尖端技术。
在此SPORE提案中,我们将结合标准护理支持每个拟议项目
临床病理学服务-如肿瘤的组织学特征,
蛋白质表达和肿瘤DNA的大规模平行测序-以及创新的新技术。之间
该项目将采用的创新性新技术是定制的等位基因特异性PCR检测,
单个融合转录物,能够超灵敏地监测无细胞循环ALK重排,
血浆样品,循环免疫荧光和转录组学,用于同时原位空间表达
多种蛋白质和转录物参与各种生化途径,以及多路离子束成像
以提供癌症内和癌旁免疫细胞浸润的高级评估。
英文摘要
Project Summary:
The Integrated Pathology and Genomics Core provides state-of-the-art analytic services for lung cancer samples
spanning the full spectrum from initial sample handling and processing, to microscopic analysis by certified
anatomic pathologists, to immunophenotypic analysis, to molecular genetic and genomic analysis. This work
constitutes the backbone of lung cancer management, and enables the diagnosis and proper treatment selection
for patients with lung cancers of all types, and also enables research into cancer biology, etiology, and
management. Our pathology core has supported work that has led to major advances in the understanding of
lung cancer biology, and associated management thereof, including seminal discoveries of the importance of
mutations in EGFR, ALK, ROS1, and MET in lung cancer, the diagnosis and management of which have become
the international standard-of-care in this area of medicine. In the same manner, we intend to continue our work
to advance the understanding and care of lung cancer, by supporting the new projects proposed herein, with a
combination of standard-of-care and innovative new cutting-edge technologies.
In this SPORE proposal, we will support each of the proposed projects with a combination of standard-of-care
clinical pathology services - such as histologic characterization of tumors, immunohistochemical assessment of
protein expression, and massively parallel sequencing of tumor DNA - and innovative new techniques. Among
the innovative new techniques to be deployed for this project are customized allele-specific PCR assays for
individual fusion transcripts to enable ultrasensitive monitoring of cell-free circulating ALK rearrangements in
plasma samples, cyclic immunofluorescence and transcriptomics for simultaneous in situ spatial expression of
multiple proteins and transcripts involved in various biochemical pathways, and multiplexed ion beam imaging
to provide high-order assessment of immune cell infiltrates within and adjacent to cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2
-
批准号:10673932
-
项目类别:
-
资助金额:$37.98万
-
财政年份:2022
-
负责人:David A Barbie
-
依托单位:
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
-
批准号:10673920
-
项目类别:
-
资助金额:$218.92万
-
财政年份:2022
-
负责人:David A Barbie
-
依托单位:
Admin Core
-
批准号:10673922
-
项目类别:
-
资助金额:$31.22万
-
财政年份:2022
-
负责人:David A Barbie
-
依托单位:
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade
-
批准号:10250392
-
项目类别:
-
资助金额:$82.64万
-
财政年份:2017
-
负责人:David A Barbie
-
依托单位:
Targeting the cytokine circuitry of KRAS-driven lung cancer
-
批准号:10424442
-
项目类别:
-
资助金额:$40.74万
-
财政年份:2015
-
负责人:David A Barbie
-
依托单位:
Targeting the cytokine circuitry of KRAS-driven lung cancer
-
批准号:9042321
-
项目类别:
-
资助金额:$39.46万
-
财政年份:2015
-
负责人:David A Barbie
-
依托单位:
Targeting the cytokine circuitry of KRAS-driven lung cancer
-
批准号:10172854
-
项目类别:
-
资助金额:$41.57万
-
财政年份:2015
-
负责人:David A Barbie
-
依托单位:
Targeting the cytokine circuitry of KRAS-driven lung cancer
-
批准号:10670932
-
项目类别:
-
资助金额:$40.74万
-
财政年份:2015
-
负责人:David A Barbie
-
依托单位:
Targeting the cytokine circuitry of KRAS-driven lung cancer
-
批准号:9263834
-
项目类别:
-
资助金额:$39.46万
-
财政年份:2015
-
负责人:David A Barbie
-
依托单位:
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer
-
批准号:8317974
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2010
-
负责人:David A Barbie
-
依托单位:
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer
-
批准号:8530978
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2010
-
负责人:David A Barbie
-
依托单位:
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer
-
批准号:7990096
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2010
-
负责人:David A Barbie
-
依托单位:
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer
-
批准号:8133466
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2010
-
负责人:David A Barbie
-
依托单位:
海外基金